Search

1. The effect on renal Na and water excretion of increasing the NaCl concentration of blood supplying the brain was investigated in conscious water‐loaded sheep. Intracarotid infusion ot 4 M‐NACl at 0–8 ml./min for 60 min was compared with equivalent intrajugular infusion. 2. A more rapid increase in renal Na excretion and urine osmolality occurred with the intracarotid infusions than with intrajugular infusions. 3. Intracarotid infusions of 2 M sucrose or fructose at 1–6 ml./min for greater increase in renal Na excretion, urine osmolality and a decrease in urine flow rate. 4. The results suggest that there are receptors in the brain sensitive to changes in extracellular tonicity which influence renal Na excretion. It is possible that changes in ADH secretion alone mediate the early natriuresis seen with intracarotid hypertonic infusions although an alternative concurrent mechanism cannot be ruled out.

We examined the interaction of SC-46542 [des(Phe106, Gly107, Ala115, Gln116)-AP(103-126)], a non-guanylate cyclase-linked atriopeptin (AP) binding site ligand, with thiorphan, an inhibitor of endopeptidase 24.11, on mean arterial pressure, urine flow, urinary sodium excretion and plasma AP immunoreactivity in conscious rats. The coadministration of SC-46542 (16 micrograms/kg/min) and thiorphan (30 mg/kg i.v. bolus) produced a greater diuresis and natriuresis (but had no effect on mean arterial pressure) than administration of either compound alone; plasma APir increased 2-fold during coadministration of SC-46542 and thiorphan (from 325 +/- 46 to 676 +/- 86 pg/ml). Administration of SC-46542 or thiorphan alone had small or no effects on mean arterial pressure, urine flow, urinary sodium excretion or plasma APir. Converting enzyme inhibition did not contribute to the effects of thiorphan since coadministration of captopril plus SC-46542 produced effects similar to SC-46542 alone. When a near threshold infusion of AP(103-126) was combined with the coadministration of SC-46542 and thiorphan, there was a potentiation of the depressor, diuretic and natriuretic responses. Neither SC-46542 nor thiorphan alone had these effects. SC-46542 potentiated the depressor but not diuretic or natriuretic responses to low dose AP(103-126) infusion; thiorphan had little or no effect on the responses to low dose AP(103-126). We conclude that blockade of non-guanylate cyclase-linked AP binding sites with SC-46542 combined with inhibition of AP degradation by endopeptidase 24.11 with thiorphan increases diuresis and natriuresis more than inhibition of either system alone.(ABSTRACT TRUNCATED AT 250 WORDS)

The properties of a novel nonpeptidic angiotensin II (AII) receptor antagonist, 2,5-dibutyl-2,4-dihydro-4-([2-(1H-tetrazol-5-yl)(1,1'-biphenyl) -4'-yl]methyl)-3H-1,2,4-triazol-3-one (SC-51316), are described. SC-51316 inhibited [125I]AII binding selectively to the AT1 receptor with IC50 values of 3.6 and 5.1 nM in rat adrenal cortical and rat uterine membrane preparations, respectively. The compound was a competitive and reversible antagonist of AII-mediated contraction of rabbit aortic rings with a pA2 of 8.86. In addition, SC-51316 inhibited AII-induced aldosterone release from rat adrenal zona glomerulosa cells and blocked inhibition of renin release by AII from rat kidney slices with pA2 values of 8.62 and 8.9, respectively. The agent (0.1 mM) did not inhibit angiotensin-converting enzyme or plasma renin activity. These data demonstrate that SC-51316 is a potent AII receptor antagonist which may prove to be useful as a pharmacologic tool for studying the role of the renin-angiotensin system in cardiovascular diseases.

The present investigation was undertaken to define the hemodynamic mechanisms by which the selective cyclic GMP phosphodiesterase inhibitor zaprinast (M&B 22,948; 2-o-propoxy-phenyl-8-azapurin-6-one) lowers mean arterial pressure (MAP). Anesthetized rats were instrumented with electromagnetic or pulsed-Doppler flow probes to measure cardiac output or regional blood flow, respectively, and catheters to record MAP, left ventricular pressure and administer drugs. Zaprinast (0.33-2.0 mg.min-1.kg-1) produced dose-dependent decreases in MAP (maximum = -39 +/- 6 mm Hg) and total peripheral resistance (maximum = -45 +/- 5%) when infused i.v. The greatest reductions in regional vascular resistance were observed in the mesenteric bed, with smaller decreases in the hindquarters and renal beds. Cardiac output increased (maximum = 22 +/- 7%) during the infusion of zaprinast; however, heart rate was only minimally affected. These increases in cardiac output were still evident in animals pretreated with beta adrenergic and muscarinic receptor antagonists. At the lowest dose, zaprinast tended to increase maximal first derivative of left ventricular pressure, whereas, at higher doses maximal first derivative of left ventricular pressure was depressed or unchanged. Additional studies were performed to examine the effect of the cyclic GMP phosphodiesterase inhibitor on the pressor and vasoconstrictor activity of phenylephrine and angiotensin II. The increases in MAP and total peripheral resistance produced by these agents were attenuated markedly during continuous infusion of zaprinast (1 mg.min-1.kg-1). These data suggest that zaprinast lowers MAP by decreasing peripheral vascular resistance and by antagonizing the actions of endogenous neurohumoral vasoconstrictor systems.

Adult ewes were studied to determine the effects of barbiturate anesthesia on renal function and the natriuretic response to renal vasodilation by papaverine and acetylcholine. During a period of consciousness, renal blood flow, glomerular filtration rate, urinary Na excretion (UNaV) and arterial blood pressure were monitored. Renal blood flow was maximally increased by renal arterial infusion of papaverine or acetylcholine and changes in renal function were observed. The sheep were subsequently anesthetized and the experimental protocol was repeated. Barbiturate anesthesia resulted in statistically significant increases in glomerular filtration rate, UNaV and blood pressure. Calculated fractional Na excretion also increased significantly. During consciousness, maximal renal vasodilation by papaverine or acetylcholine did not increase UNaV or fractional Na excretion. During anesthesia, both papaverine and acetylcholine produced large increases in both UNaV and fractional Na excretion. These data indicate that renal vasodilation per se is not a sufficient condition to increase UNaV and suggest that barbiturate anesthetics can alter renal function in such a manner as to render drugs, which are not natriuretic during consciousness, effective natriuretic agents during anesthesia.

Peripheral blood corticosteroid levels were determined in nine species of Australian marsupial (Eastern grey kangaroo, black-tailed, Bennett's and pademelon wallabies, quokka, wombat, koala and Western native and tiger cats), one species of monotreme (echidna) and one placental Australian mammal (dingo). Animals were obtained or bled with minimal disturbance and came from areas considered to have adequate sodium content of the vegetation. Aldosterone, corticosterone, cortisol, 11-deoxycorticosterone and 11-deoxycortisol were measured and levels found to be similar to five introduced eutherian species (sheep, cow, dog, fox and man) with the exception of the koala and the wombat. Cortisol was the predominant corticosteroid, except in the koala, which produced corticosterone in relatively the greatest quantity, and the wombat which produced more 11-deoxycortisol. Steroid levels were generally low in the wombat. ACTH administered to the koala changed its pattern of corticosteroid secretion from predominantly corticosterone to cortisol. In the dingo, administration of ACTH caused rises in corticosteroid levels similar to those seen in most other eutherian mammals.